Checkpoint Inhibitors and SBRT for mCRPC

The participants receive treatment for 52 weeks, including four cycles of ipilimumab andnivolumab with or without concomitant SBRT (24 Gray in three fractions) to a single softtissue or bone metastasis, followed by 10 cycles of nivolumab. Participants are followeduntil progression, death, or for 12 months after the end of treatment.Biopsies from metastatic sites are collected at baseline, before the third treatment, andat the end of treatment. Blood sampling for immune monitoring and circulating tumor DNAis performed consecutively at baseline and every radiographic assessment.